Skip to main content
Decorative image of the AMR Learning Lounge

Impact of a Procalcitonin-Based Protocol on Antibiotic Exposure and Costs in Critically Ill Patients

SUMMARY

Adopting a procalcitonin-based (PCT) protocol for diagnosing and managing sepsis was shown to be associated with decreased antibiotic use and cost savings without jeopardizing mortality rates. Assistant Professor Jarva Chow, MD and her coauthors implemented this study over three years in an ICU setting and saw an average savings of over $1,200 per patient after adopting PCT protocols.

FEATURED EXPERTS

Jarva Chow, MD, Assistant Professor of Anesthesia and Critical Care at the University of Chicago


GET STARTED

Read the journal article at the Society of Critical Care Medicine.

Read Time: 18 minutes


We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.

We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.


U.S. bioMérieux Solutions

US Solutions

VIDAS® B•R•A•H•M•S PCT™

Detects procalcitonin, a biomarker that aids in the risk assessment for progression to severe sepsis and septic shock. PCT also aids in decision making on antibiotic therapy for patients with lower respiratory tract infections (LRTI).

PUBLISHED BY

Society of Critical Care Medicine (SCCM)
January 4, 2022


SHARE THIS ARTICLE: